in vivo News and Research

RSS
Covidien, Somanetics sign definitive merger agreement

Covidien, Somanetics sign definitive merger agreement

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Evidence-based review of TBI in sport

Evidence-based review of TBI in sport

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

In vivo structure of senile plaques in brains of people with Alzheimer's disease

In vivo structure of senile plaques in brains of people with Alzheimer's disease

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Pharnext closes €4.8-million Series A funding round

Pharnext closes €4.8-million Series A funding round

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

Research findings open door to development of new therapies for lymphomas, leukemias

Research findings open door to development of new therapies for lymphomas, leukemias

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Microscopic image sensor to speed up detection of tumors

Microscopic image sensor to speed up detection of tumors

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

YM BioSciences raises $3.2M through non-brokered private placement of common shares

YM BioSciences raises $3.2M through non-brokered private placement of common shares

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.